New shot could ease chronic heel pain

NCT ID NCT06169319

Completed Symptom relief Sponsor: Endo USA Inc., a Keenova Therapeutics Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two doses of an injected biologic called EN3835 (collagenase) against a placebo in 231 adults with plantar fasciitis lasting at least 6 months. The goal was to see if it reduces daily heel pain and improves foot function over 12 weeks. Results are complete and will show whether this approach offers relief for people who haven't gotten better with standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Collagenase clostridium histolyticum (CCH) injection
What this could lead to: If it works, this could provide a new injection-based option to reduce heel pain and improve foot function for people with stubborn plantar fasciitis.
What could go wrong: This is a mid-stage trial with only 231 participants. The treatment may not prove more effective than placebo, and injections can cause local side effects like swelling or bruising.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plantar fasciitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLANTAR FASCIITIS

Contacts and locations

Locations

Endo Clinical Site 1

Georgetown, Texas, 78628, United States
Endo Clinical Site 2

Pasadena, Maryland, 21122, United States
Endo Clinical Site 3

Pinellas Park, Florida, 33782, United States
Endo Clinical Site 4

Bedford, Texas, 76021, United States
Endo Clinical Site 5

Salt Lake City, Utah, 84107, United States
Endo Site 10

Tarzana, California, 91356, United States
Endo Site 11

Fresno, California, 93710, United States
Endo Site 12

Suffolk, Virginia, 23434, United States
Endo Site 13

Corona, California, 92882, United States
Endo Site 14

Sweetwater, Florida, 33172, United States
Endo Site 15

Houston, Texas, 77027, United States
Endo Site 16

Los Angeles, California, 90010, United States
Endo Site 17

Dallas, Texas, 75208, United States
Endo Site 18

Dallas, Texas, 75251, United States
Endo Site 19

Grand Rapids, Michigan, 49525, United States
Endo Site 20

Castro Valley, California, 94546, United States
Endo Site 21

San Francisco, California, 94115, United States
Endo Site 22

San Antonio, Texas, 78258, United States
Endo Site 23

Stonecrest, Georgia, 30038, United States
Endo Site 24

Burleson, Texas, 76028, United States
Endo Site 25

Moore, Oklahoma, 73160, United States
Endo Site 26

Dallas, Texas, 75235, United States
Endo Site 27

Missoula, Montana, 59804, United States
Endo Site 28

O'Fallon, Illinois, 62269, United States
Endo Site 30

Fort Worth, Texas, 76104, United States
Endo Site 31

North Chicago, Illinois, 60064, United States
Endo Site 32

Newport News, Virginia, 23606, United States
Endo Site 33

Overland Park, Kansas, 66211, United States
Endo Site 34

San Antonio, Texas, 78229, United States
Endo Site 35

Shreveport, Louisiana, 71101, United States
Endo Site 36

Malvern, Pennsylvania, 19355, United States
Endo Site 37

Coconut Creek, Florida, 33073, United States
Endo Site 38

Westwood, New Jersey, 07675, United States
Endo Site 39

Portland, Oregon, 97202, United States
Endo Site 40

Los Angeles, California, 90063, United States
Endo Site 6

Encinitas, California, 92024, United States
Endo Site 7

Lawrenceville, Georgia, 30043, United States
Endo Site 8

Tucson, Arizona, 85712, United States
Endo Site 9

McAllen, Texas, 78501, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.